<DOC>
	<DOCNO>NCT00869271</DOCNO>
	<brief_summary>The purpose study investigate whether TAC plus FOLFOX4 able improve resection rate overall survival patient receive primary colorectal tumor resection give FOLFOX4 .</brief_summary>
	<brief_title>Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy ( TAC ) Treatment Unresectable Liver Metastasis Colorectal Cancer</brief_title>
	<detailed_description>We administer three cycle FOLFOX4 plus TAC ( oxaliplatin , FUDR MMC ) FOLFOX4 primary colorectal tumor resect patient unresected liver metastasis . The study endpoints resection rate liver metastasis , progression-free survival , overall survival evaluate intent-to-treat analysis .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>age &lt; 75 year histologically proven adenocarcinoma colon rectum severe major organ dysfunction WHO performance status 0 1 prior cancer therapy measurable unresectableliver metastasis without metastasis age &gt; = 75 severe major organ dysfunction WHO performance status &gt; 1 prior cancer therapy metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>